Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06802380 · ClinicalTrials.gov registry record · Phase 1
Neuromodulation in Patients With Pulmonary Arterial Hypertension
A Phase 1 study, sponsored by University of Oklahoma.
- Not yet
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT06802380 is a Phase 1 study that has not yet begun recruiting, run by University of Oklahoma. The registered enrollment target is 50 participants.
The verdict
NCT06802380, a Phase 1 study, has not yet begun recruiting, sponsored by University of Oklahoma.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Patients with Group 1 pulmonary hypertension will be enrolled in this study. Investigators will test the hypothesis of low-level tragal stimulation in patients with pulmonary hypertension. The study will be conducted over 4 weeks and patients will undergo low-level tragus stimulation for 1 hour every day for 4 weeks. At baseline the following tests will be conducted-6-minute walk distance, vascular function testing using noninvasive device and blood samples will be collected. Patient will also undergo a limited echocardiography to assess right ventricular function. After 4 weeks of stimulation patients will come back to undergo these tests again. Investigators hypothesized that low-level tragus stimulation (neuromodulation) will lead to improvement in vascular function, 6-minute walk distance and blood based biomarkers in patients with pulmonary hypertension.
Interventions
- DEVICE Sham stimulation
- DEVICE Low-level tragus stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-09-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06802380
The ClinicalTrials.gov registry entry for NCT06802380 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham stimulation is the first listed.
NCT06802380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06802380 about?
NCT06802380 is a clinical study titled "Neuromodulation in Patients With Pulmonary Arterial Hypertension". Patients with Group 1 pulmonary hypertension will be enrolled in this study. Investigators will test the hypothesis of low-level tragal stimulation in patients with pulmonary hypertension. The study will be conducted over 4 weeks and patients will undergo low-level tragus stimulation for 1 hour ever...
What is the current status of trial NCT06802380?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-09-01. Estimated completion is 2026-12-31.
What interventions are being tested in trial NCT06802380?
The interventions under investigation include: Sham stimulation (DEVICE), Low-level tragus stimulation (DEVICE).
Who is sponsoring clinical trial NCT06802380?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.